News about "AbbVie"

Ichnos Glenmark Innovation Secures USD 700M Upfront in AbbVie Licensing Deal for ISB 2001

Ichnos Glenmark Innovation (IGI) has received an upfront payment of USD 700 million from AbbVie under the terms of their recently announced global licensing agreement for IGI’s lead investigational asset, ISB 2001.

AbbVie | 09/09/2025 | By Dineshwori

AbbVie to Acquire Gilgamesh's Psychedelic Antidepressant Bretisilocin in USD 1.2 Billion Deal

AbbVie has announced a USD 1.2 billion deal to acquire Gilgamesh Pharmaceuticals’ lead candidate bretisilocin, a next-generation psychedelic compound in clinical development for treating moderate-to-severe major depressive disorder.

AbbVie | 26/08/2025 | By Mrinmoy Dey

AbbVie Announces Completion of Acquisition of Capstan Therapeutics

AbbVie has completed its acquisition of Capstan Therapeutics, bringing onboard Capstan’s tLNP platform and lead asset CPTX2309 to advance next-generation in vivo CAR-T therapies for autoimmune diseases.

AbbVie | 20/08/2025 | By Mrinmoy Dey

AbbVie to Invest USD 195 Million to Expand API Manufacturing in US

AbbVie will invest USD 195 million to expand active pharmaceutical ingredient manufacturing at its North Chicago plant, strengthening US production capacity for current and next-generation medicines.

AbbVie | 13/08/2025 | By Mrinmoy Dey

Glenmark's IGI Signs Licensing Deal with AbbVie for Investigational Cancer Therapy

AbbVie to lead global development, manufacturing and commercialisation of Ichnos Glenmark Innovation’s (IGI) investigational cancer therapy ISB 2001 in North America, Europe, Japan, and Greater China, while Glenmark will take these roles in emerging markets.

AbbVie | 11/07/2025 | By Dineshwori |  107

AbbVie and REGENXBIO Update on ABBV-RGX-314 Clinical Program

AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector® to deliver gene therapy to the suprachoroidal space of the eye.

AbbVie | 15/01/2025 | By Aishwarya |  177

AbbVie to Acquire Nimble Therapeutics to Expand its Immunology Pipeline

AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets.

AbbVie | 18/12/2024 | By Aishwarya |  386

AbbVie Announces Acquisition of Aliada Therapeutics

Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in a Phase 1 clinical trial.

AbbVie | 13/12/2024 | By Aishwarya |  176

AbbVie Receives European Commission Approval of ELAHERE

ELAHERE is the first and only folate receptor alpha (FR?)-directed antibody drug conjugate (ADC) medicine approved in the European Union (EU), as well as Iceland, Liechtenstein, Norway, and Northern Ireland.

AbbVie | 18/11/2024 | By Aishwarya |  181

AbbVie and EvolveImmune to Develop Next-Gen Cancer Biotherapeutics

EvolveImmune's proprietary EVOLVE platform is designed to deliver potent, selective and integrated T-cell co-stimulation to amplify and sustain the tumor killing capacity of the T-cells.

AbbVie | 01/11/2024 | By Aishwarya |  227